This study evaluates the cost-effectiveness and budget impact to US payers of point-of-care nucleic acid amplification tests (NAAT) for group A streptococcus.
Eliza Kruger, MHEcon
Advertisement
Articles by Eliza Kruger, MHEcon
Advertisement
Latest Updated Articles
- US Cost-effectiveness and Budget Impact of Point-of-Care NAAT for Streptococcus
Published: May 12th 2021 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Reduction in Food Allergies Found After Guideline-Directed Early Peanut Exposure
2
FDA Expands Semaglutide Label to Reduce Cardiovascular Risk in Adults With Type 2 Diabetes
3
Tezepelumab Becomes First TSLP-Targeting Biologic Approved by FDA for CRSwNP
4
Brensocatib Reduced Symptom Burden, Neutrophil Serine Proteases Activity in Bronchiectasis
5
